Metis Global Partners LLC Purchases Shares of 29,319 Organogenesis Holdings Inc. (NASDAQ:ORGO)

Metis Global Partners LLC acquired a new position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 29,319 shares of the company’s stock, valued at approximately $84,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Pallas Capital Advisors LLC acquired a new position in Organogenesis during the second quarter worth approximately $38,000. Delap Wealth Advisory LLC acquired a new position in shares of Organogenesis during the 2nd quarter worth approximately $40,000. Allspring Global Investments Holdings LLC raised its stake in Organogenesis by 4,989.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after acquiring an additional 15,369 shares during the period. Mackenzie Financial Corp lifted its holdings in Organogenesis by 46.1% during the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock valued at $68,000 after purchasing an additional 7,678 shares during the last quarter. Finally, CWM LLC boosted its position in Organogenesis by 301.8% during the second quarter. CWM LLC now owns 25,617 shares of the company’s stock worth $72,000 after purchasing an additional 19,242 shares during the period. 49.57% of the stock is owned by institutional investors.

Organogenesis Price Performance

Shares of ORGO opened at $4.08 on Wednesday. The company’s 50-day moving average is $3.05 and its 200-day moving average is $2.84. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The firm has a market capitalization of $540.93 million, a PE ratio of -66.83 and a beta of 1.60. Organogenesis Holdings Inc. has a fifty-two week low of $2.16 and a fifty-two week high of $4.70.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The firm had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. During the same period in the prior year, the firm earned $0.02 EPS. Equities analysts forecast that Organogenesis Holdings Inc. will post -0.12 EPS for the current year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.